drugset

drugset / Trial / NCT01420146

Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients

NCT01420146 ↗

Phase 1 Completed 20 enrolled Jules Bordet Institute

NaSingle-groupOpen-labelDiagnostic

Summary

Evaluation of the diagnostic potential of HER2 imaging using zirconium 89 labelled trastuzumab.

Timeline

Start: 2011-08
Primary completion: 2015-09
Completion: 2015-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Zr89-trastuzumab	Monoclonal antibody	—	—

Indications